Following the positive outcomes of the FORTITUDE® and APTITUDE® trials, Amaranth Medical continued its development to create a bioresorbable scaffold that provides the same strength and flexibility of metallic drug-eluting stents, the current standard of care.
The MAGNITUDE® sirolimus-eluting bioresorbable scaffold (BRS) is the result of this development program. The sub-100 µm MAGNITUDE® is currently being evaluated in a clinical trial titled RENASCENT III, which has completed enrollment. Amaranth will provide additional clinical updates on the RENASCENT III trial as they become available.
For more information about the RENASCENT III Trial, please visit: